Download PDF
Onkologische Welt 2011; 02(05): 203-210
DOI: 10.1055/s-0038-1632083
Kongressnachlese WCGC 2011
Schattauer GmbH

13. ESMO Weltkongress Gastrointestinale Tumoren: Die Entwicklung zielgerichteter Therapien im Blick

Further Information

Publication History

Publication Date:
02 February 2018 (online)

    Permissions and Reprints

Der 13. Weltkongress zu gastrointestinalen Tumoren stand in diesem Jahr unter der Leitung von Mario Dicato, MD vom Luxembourg Medical Center und Eric Van Cutsem, MD, PhD, vom Universitätskrankenhaus Gasthuisber, Leuven, Belgien. Der Kongress thematisiert die Malignitäten aller Teile des Gastrointestinaltrakts sowie Aspekte, die im Zusammenhang mit der Betreuung von Patienten mit GI-Tumoren stehen, inklusive Screening, Diagnose und den neuesten Behandlungsoptionen für häufige und seltene Tumore, betonen Dicato und Van Cutsem in ihrem Geleitwort zum Kongress.

 

  • Literatur

  • 1 NCCN.. Practice Guidelines in Oncology. Hepatocellular Cancer v. 1.2010.Available at: www.nccn.org.
  • 2 Llovet JM. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
    CrossrefPubMedGoogle Scholar
  • 3 Poon RT.. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360.
    CrossrefPubMedGoogle Scholar
  • 4 Cheng A.. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2011: 4000.
    PubMedGoogle Scholar
  • 5 Park J-W. et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983.
    CrossrefPubMedGoogle Scholar
  • 6 Raoul JL. et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). ASCO Meeting abstracts. 2009: 4577.
    PubMedGoogle Scholar
  • 7 Toh et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis ASCO Meeting Abstract 2009: 4581.
  • 8 Zhu AX. et al. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2010: 4083.
    PubMedGoogle Scholar
  • 9 Zhu AX. et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011 Apr 27. doi: 10.1002/cncr.26165. [Epub ahead of print]
  • 10 Santoro A. et al. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 103 (06) 837-844.
    CrossrefPubMedGoogle Scholar
  • 11 Gordon MS. et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts. 2011: 3010.
    PubMedGoogle Scholar
  • 12 Abou Alfa G. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304 (19) 2154-2160.
    CrossrefPubMedGoogle Scholar
  • 13 Thomas MB. et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27 (06) 843-850.
    CrossrefPubMedGoogle Scholar
  • 14 Finn RS. et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2011: 4074.
    PubMedGoogle Scholar
  • 15 Hubbard et al. Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745. ASCO Meeting Abstracts 2011: 4116.
  • 16 Demetri GD. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
    CrossrefPubMedGoogle Scholar
  • 17 Verweij J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
    CrossrefPubMedGoogle Scholar
  • 18 von Mehren M., Watson JV.. Gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2005; 19: 547-564.
    CrossrefPubMedGoogle Scholar
  • 19 Demetri GD. et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-3147.
    CrossrefPubMedGoogle Scholar
  • 20 Reichardt P. et al. J Clin Oncol 2010; 28: 10017
    Crossref
  • 21 Novartis. Pressemitteilung vom 11. April 2011
  • 22 George S. et al. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). ASCO Meeting Abstracts. 2011: 10007.
    PubMedGoogle Scholar
  • 23 Bosman FT. et al. WHO classification of Tumours of the digestive system 2010
    PubMed
  • 24 Yao JC. et al. One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
    CrossrefPubMedGoogle Scholar
  • 25 Lawrence B. et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 111-134.
    CrossrefPubMedGoogle Scholar
  • 26 Yao JC. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
    CrossrefPubMedGoogle Scholar
  • 27 Yao JC. et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
    CrossrefPubMedGoogle Scholar
  • 28 Pavel M. et al. Everolimus improves progression-free survival (PFS) regardless of baseline chromogranin A (CgA) and neuron-specific enolase (NSE) levels in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3). Annals of Oncology 2011; 22 (Suppl. 05) Abstract 0011.
    CrossrefPubMedGoogle Scholar
  • 29 de Vries E. et al. Annual ASCO Meeting. , Chicago, IL, 2011; Abstract 35A.
    Google Scholar
  • 30 Motzer RJ. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer. 2007; 5 (Suppl. 04) 301s, Abstract 4509.
    Google Scholar
  • 31 Demetri GD. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368 9544 1329-1338.
    CrossrefPubMedGoogle Scholar
  • 32 Raymond E.. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
    CrossrefPubMedGoogle Scholar
  • 33 Raymond E.. et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). ASCO Meeting Abstracts. 2011: 4008.
    PubMedGoogle Scholar
  • 34 Heinrich MC.. In vitro activity of novel KIT/ PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. ASCO Meeting Abstract. 2010: 10007.
    PubMedGoogle Scholar
  • 35 Hornick JL, Fletcher CD.. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007; 38: 679-687.
    CrossrefPubMedGoogle Scholar
  • 36 Heinrich MC. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
    CrossrefPubMedGoogle Scholar
  • 37 Reichardt P.. et al. Detailed analysis of survival and safety with sunitinib in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol. 2008; 26 (Suppl. 15) 565s, Abstract 10548.
    CrossrefGoogle Scholar
  • 38 Van Cutsem et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOR). Annals of Oncology 2011; 22 (Suppl. 5): Abstract O-0024.